Elevance Health (ELV) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Elevance Health (ELV) is forecast to report Q2 earnings of $9.20 per share, a 9.1% year-over-year decline, on revenues of $48.13 billion, an 11.4% increase. The consensus EPS estimate has remained unchanged over the past 30 days. Analysts anticipate a higher Benefit Expense Ratio of 88.4% compared to 86.3% last year, and a slight increase in total medical membership to 45.83 million, primarily driven by growth in Medicare Advantage offsetting declines in Medicaid and Medicare Supplement. Shares of ELV have underperformed the S&P 500 over the last month, falling 11.4% against the index's 4% gain, and currently hold a Zacks Rank #3 (Hold).

Analysis

Elevance Health (ELV) is projected to report a dichotomous second quarter, featuring robust top-line growth alongside significant margin compression. Analysts forecast an 11.4% year-over-year revenue increase to $48.13 billion, primarily driven by strong growth in premiums (+11.9%) and product revenue (+11.1%). However, this growth is overshadowed by a forecasted 9.1% decline in earnings per share to $9.20. The primary cause for this earnings pressure is a substantial projected increase in the Benefit Expense Ratio to 88.4% from 86.3% in the prior-year quarter, indicating that rising medical costs are outpacing revenue gains. Membership metrics reveal a strategic shift, with total membership growing marginally to 45.83 million, largely due to strong expansion in the high-value Medicare Advantage segment, which is expected to reach 2.24 million members. This positive is tempered by anticipated declines in Medicaid and Medicare Supplement enrollment. The stock's recent 11.4% underperformance against the S&P 500 suggests that investors are already pricing in these margin concerns ahead of the earnings release, a sentiment reinforced by the neutral Zacks Rank #3 (Hold).

Key Decisions for Investors

• Investors should focus intently on the reported Benefit Expense Ratio, as any deviation from the projected 88.4% will be the primary driver of the stock's post-earnings reaction.
• Given the stock's recent underperformance, a neutral stance may be prudent until management provides clear guidance on its ability to control rising medical costs in the second half of the year.
• Look for confirmation of continued strength in the Medicare Advantage segment, as sustained growth here is a critical long-term positive that could offset the near-term profitability challenges.